Drugs / Rejuveinix
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03041259 | Jan 2020 → Jan 2022 | limb ischemia, peripheral arterial disease | Reven Pharmaceuticals, Inc. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rejuveinix | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03041259 ↗ |
| Route | Intravenous | “administered via intravenous (IV) injection” NCT03041259 ↗ |